Gene Expression Profiling of Contralateral Dorsal Root Ganglia Associated with Mirror-Image Pain in a Rat Model of Complex Regional Pain Syndrome Type-I

Huimin Nie1,2*, Boyu Liu1,2,*, Chengyu Yin1, Ruixiang Chen1, Jie Wang1, Danyi Zeng1, Yan Tai2, Jingdun Xie3, Dongwei He4,5, Chengyu Yin1

1Department of Neurobiology and Acupuncture Research, The Third Clinical Medical College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Hangzhou, 310053, People’s Republic of China; 2Academy of Chinese Medicine Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, People’s Republic of China; 3Department of Anesthesiology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Collaborative Innovation for Cancer Medicine, Guangzhou, Guangdong, 510060, People’s Republic of China; 4Laboratory of Pathology, Hebei Cancer Institute, the Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, People’s Republic of China

*These authors contributed equally to this work

Introduction

Mirror-image pain (MIP) is a mysterious pain phenomenon which is accompanied with many clinical pain conditions. MIP develops from the healthy body region which is contralateral to the actual injured site. MIP is typically characterized by increased mechanical hypersensitivity on the uninjured mirror-image body side. It can be triggered in response to light touch/pressure stimuli, which are normally perceived as innocuous. Patients with chronic pain, such as complex regional pain...
syndrome (CRPS) and atypical facial pain, etc., can develop MIP to the unaffected body side.\textsuperscript{6,7}

Complex regional pain syndrome type-I (CRPS-I) is a chronic pain condition that usually impacts the extremities of the patients.\textsuperscript{8} It is usually triggered by an initial injury, including tissue ischemia, fractures, or surgery in the extremity and develops into a chronic pain condition that impacts the life quality of the patients.\textsuperscript{9–11} One of the clinical features of CRPS-I is the MIP developed in the unaffected extremities.\textsuperscript{7,12,13} CRPS-I patients developed hypersensitivity to capsaicin, thermal, and mechanical stimuli in the unaffected extremities.\textsuperscript{12} Furthermore, we and others also observed thermal and mechanical hypersensitivity in the unaffected hind limb of a rat model of CRPS-I, suggesting the occurrence of MIP in animal models.\textsuperscript{14–18}

At present, the pathogenesis of MIP still remained largely unknown. However, certain possible mechanisms have been proposed to contribute to MIP.\textsuperscript{19} Spinal glial activation has been observed in the contralateral spinal cord dorsal horn of MIP model animals.\textsuperscript{15,17,20} Pharmacological blocking spinal glia metabolism and proinflammatory cytokines (including TNF-α, IL-1β, and IL-6) significantly alleviates MIP, suggesting spinal glial and proinflammatory cytokines are involved in MIP.\textsuperscript{2} In addition to the central mechanism, peripheral mechanisms have also been proposed for MIP.\textsuperscript{4,21} It is reported that TNF-α produced from ipsilateral injured DRG can diffuse to the contralateral side via cerebrospinal fluid and activates satellite cells to produce NGF, which promotes nociceptor excitability on the contralateral side and induces MIP.\textsuperscript{4} Although these studies provide evidence suggesting central or peripheral glia and proinflammatory cytokines are important for MIP pathogenesis, it still remains unclear how contralateral DRG is affected in chronic pain conditions and exerts pain signals that may contribute to MIP.

In order to study the molecular mechanisms underlying MIP, we performed a genome-wide expression profiling of DRG innervating contralateral hind limbs of a rat model of CRPS-I by means of RNA-Seq. We obtained gene expression profiles and identified differentially expressed genes (DEGs) in CPIP model rats vs sham rats. We studied the major functions or signaling pathways that these DEGs may be involved in. We further screened the genes which might contribute to nociception and pain processing during MIP. Thus, this study provides novel insights into understanding the peripheral mechanisms contributing to MIP.

Materials and Methods

Animals

Male adult Sprague-Dawley rats weighing 300–320 g were purchased from Shanghai Laboratory Animal Center, Chinese Academy of Sciences. Rats were randomly assigned to each group and housed in the Laboratory Animal Center of Zhejiang Chinese Medical University accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) under standard environmental conditions (12 hour light–dark cycles and 24±2°C). Rats had free access to food and water. The animals were given 1 week to adapt to the new environment before formal experiment. All experimental procedures were carried out in accordance with the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) and approved by the Animal Ethics Committee of Zhejiang Chinese Medical University (Permission Number: ZSLL-2017-183).

CPIP Rat Model Establishment

The CPIP model was established by prolonged hind paw ischemia and reperfusion as reported before.\textsuperscript{16,22} Anesthesia was induced by intraperitoneal injection of 50 mg/kg of sodium pentobarbital and was maintained at a dose of 20 mg/kg/h. Glycerin was applied to the ankle joints of rats. Afterwards, a Nitrile 70 Durometer O-ring (Gaohui Rubber & Plastic Co., Ltd., Shanghai, China) with an inner diameter of 7/32 inch (5.5 mm) was tightly passed around the right hind limb just proximal to the ankle joint. The O-ring was cut off 3 hours later for reperfusion. Sham rats received the same anesthesia procedure but a cut O-ring, which could not block blood flow, was applied to the same part as the CPIP model rats.

Determination of Mechanical Allodynia

Before baseline test, rats were habituated to the testing environment every day for 3 consecutive days. Rats were individually placed on an elevated mesh floor, covered with transparent Plexiglas chambers. Rats were habituated for 30 minutes before the test. The mechanical allodynia was measured using a series of von Frey filaments (ranging from 0.6–26 g, UGO Basile, Italy) applied perpendicularly to the mid-plantar surface of the hind paws, with sufficient force to bend the filament slightly for 5 seconds according to methods we previously used.\textsuperscript{23} Nocifensive responses were identified as an abrupt
withdrawal of the paw and licking and vigorously shaking in response to the stimulation. The threshold was determined by the "Up–Down" testing paradigm, and the 50% paw withdrawal threshold (PWT) was calculated by the nonparametric Dixon test.\textsuperscript{24,25} Behavior tests were all conducted by an experimenter blinded to experimental conditions.

**Measurement of Hind Paw Edema**

Edema was observed as an increase in hind paw diameter and measured by a digital caliper, and was calculated as the difference between the basal value and the test value as described in our previous study.\textsuperscript{15} Each rat was measured three times and the mean value was calculated.

**Tissue Collection and RNA Extraction**

At day 7, rats were deeply anesthetized with sodium pentobarbital at a dose of 50 mg/kg and were perfused transcardially with 200 mL 0.9% saline (4°C). After the perfusion, the left (contralateral) side L4-6 DRG segments were collected and were immediately preserved in the RNA later solution (Thermo Fisher, USA). Total RNA was extracted using the Trizol reagent (Thermo Fisher, USA) following the manufacturer’s instructions. DNase I (Thermo Fisher, USA) was used to degrade contaminating DNA. The purity and concentration of the samples was assessed by a Nanodrop Spectrophotometer (NanoDrop Products, USA) and the RNA integrity was assessed by an Agilent 2100 Bioanalyzer (Agilent Technologies, USA).

**Immunofluorescence Staining**

At day 7, rats were deeply anesthetized with sodium pentobarbital at a dose of 50 mg/kg and were perfused transcardially with 200 mL 4% formaldehyde after 200 mL 0.9% saline (4°C). The bilateral L4-6 DRGs was harvested and post-fixed in the same fixative for 4 hours (4°C) before transferring to 15% and 30% sucrose solution (Thermo Fisher, USA). The DNA nanoballs were loaded into the patterned nanoarray and single-end 50 base reads were generated in the way of being sequenced by synthesis. The synthesized cDNA was subjected to end-repair and then was 3’ adenylated. Adaptors were ligated to the ends of these 3’ adenylated cDNA fragments. This process is to amplify the cDNA fragments with adaptors from previous step. PCR products are purified with the SPRI beads and dissolved in EB solution. The double stranded PCR products were heat denatured and circularized by the splint oligonucleotide sequence. The single-strand circle DNA (ssCir DNA) was formatted as the final library. The library was validated by the Agilent 2100 Bioanalyzer System (Agilent Technologies, USA). The DNA nanoballs were loaded into the patterned nanoarray and single-end 50 base reads were generated in the way of being sequenced by synthesis. Finally, the fragments were enriched by PCR amplification to construct a library ready for sequencing using the BGI SEQ-500 platform (BGI Group, Shenzhen, China). The RNA-Seq dataset has been deposited into the National Center for Biotechnology Information’s Gene Expression Omnibus repository with accession number GSE174299.

**Bioinformatics Analysis**

Primary sequencing data produced by RNA-Seq (raw reads) were subjected to quality control (QC). The information of total reads and mapping ratio reads is shown in Table 1. Raw reads were filtered into clean reads using...
internal software SOAP nuke (version 1.5.2), as follows: Remove reads in which unknown bases (N) are more than 10%; Remove reads with adaptors; Remove low quality reads (we define the low quality read as the percentage of base which quality is < 15 and > 50% in a read). QC of alignment was performed to determine if re-sequencing was needed. If the alignment result passed QC, down-stream analysis including gene expression, differentially

Table 1 Sequences of the Primers Used for qPCR Validation of RNA-Seq Dataset

| Gene Name | Gene ID | Primer Sequence (5′ − 3′) | Amplicon Size (bp) |
|-----------|---------|---------------------------|-------------------|
| Gpr183    | 679975  | F: 5′-GCAGAACCCACTGACCGAGATACTGACTCATGACCCAGAGCCGATGATG-3′ | 83 |
| Trn8      | 684440  | F: 5′-GGCCCTTGGACGCTGTGTAAATG3′ | 142 |
| Tbx18     | 315870  | F: 5′-GGCCCTTGGACGCTGTGTAAATG3′ | 98 |
| Egr1      | 24329   | F: 5′-GCAGAACCCACTGACCGAGATACTGACTCATGACCCAGAGCCGATGATG-3′ | 145 |
| Cxcl13    | 498335  | F: 5′-GCAGAACCCACTGACCGAGATACTGACTCATGACCCAGAGCCGATGATG-3′ | 219 |
| Slfn1     | 688900  | F: 5′-GCAGAACCCACTGACCGAGATACTGACTCATGACCCAGAGCCGATGATG-3′ | 113 |
| Gli2      | 304729  | F: 5′-GCAGAACCCACTGACCGAGATACTGACTCATGACCCAGAGCCGATGATG-3′ | 144 |
| Stk32b    | 305431  | F: 5′-GCAGAACCCACTGACCGAGATACTGACTCATGACCCAGAGCCGATGATG-3′ | 96 |
| Asgr2     | 29403   | F: 5′-GCAGAACCCACTGACCGAGATACTGACTCATGACCCAGAGCCGATGATG-3′ | 136 |
| Smoc2     | 292401  | F: 5′-GCAGAACCCACTGACCGAGATACTGACTCATGACCCAGAGCCGATGATG-3′ | 117 |
| Fcgr1a    | 295279  | F: 5′-GCAGAACCCACTGACCGAGATACTGACTCATGACCCAGAGCCGATGATG-3′ | 140 |
| Osr2      | 315039  | F: 5′-GCAGAACCCACTGACCGAGATACTGACTCATGACCCAGAGCCGATGATG-3′ | 139 |
| Snel1     | 316638  | F: 5′-GCAGAACCCACTGACCGAGATACTGACTCATGACCCAGAGCCGATGATG-3′ | 89 |
| Siglecl   | 311426  | F: 5′-GCAGAACCCACTGACCGAGATACTGACTCATGACCCAGAGCCGATGATG-3′ | 119 |
| Myl1      | 56781   | F: 5′-GCAGAACCCACTGACCGAGATACTGACTCATGACCCAGAGCCGATGATG-3′ | 103 |
| Myo2      | 306616  | F: 5′-GCAGAACCCACTGACCGAGATACTGACTCATGACCCAGAGCCGATGATG-3′ | 107 |
| Capg      | 297339  | F: 5′-GCAGAACCCACTGACCGAGATACTGACTCATGACCCAGAGCCGATGATG-3′ | 97 |
| Retsat    | 246298  | F: 5′-GCAGAACCCACTGACCGAGATACTGACTCATGACCCAGAGCCGATGATG-3′ | 128 |
expressed genes, cluster analysis, Gene Ontology (GO) enrichment analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis, and Gene Set Enrichment Analysis (GSEA) analysis were then performed.

Cluster Analysis and Screening of Differentially Expressed Genes
Methods were adopted as before. Briefly, distances of expressed genes were calculated using the Euclidean method. The sum of the squared deviations algorithm was used to calculate distance. The cluster analysis and heat map visualization of gene expression patterns was performed using the “heatmap” package in the R software of Bioconductor. Differentially expressed mRNAs with statistical significance were identified through Volcano Plot filtering. The threshold required for the results to be considered significant was as follows: q-value ≤ 0.001 and fold change ≥ 1.5 or ≤ 0.667.

Functional Enrichment Analysis of DEGs
Functional enrichment analysis was performed through the functional annotation package “cluster Profiler” in R studio software (RStudio, Boston, MA, USA). GO and KEGG enrichment analysis were also conducted. For each enriched function term, the Q-value of enriched functions and the Q-value by multiple testing corrections were calculated by “cluster Profiler” package in R studio software. The GO functional and KEGG pathway enrichment analysis were performed for DEGs using the Database for Annotation, Visualization, and Integrated Discovery (DAVID) online tools (http://www.geneontology.org and http://www.genome.jp/kegg).

GSEA Analysis
Gene set enrichment analysis (GSEA) was performed according to methods previously described. We chose the top 10 most significantly upregulated pathways from GSEA analysis. The gene sets were downloaded from the Molecular Signatures Database v7.1 (https://www.gsea-msigdb.org/gsea/msigdb/index.jsp). A FDR ≤ 0.25 and NES > 1.0 were adopted as the criterion for judging significance.

Real-Time Quantitative PCR (qPCR) Analysis
According to the manufacturer’s instruction, the extracted total RNA from the DRGs was reverse transcribed into cDNA using random hexamers primers (TaKaRa Bio Inc., China). The sequences of all primers used are shown in Table 1. qPCR was performed using SYBR Green I Master (Roche, Switzerland) in 20 µL reaction system according to the manufacturer’s protocol. qPCR was performed with the LightCycler 480 real-time PCR system (Roche, Switzerland). Each reaction was performed in triplicate and normalized to β-actin gene expression. The CT value of each well was determined using the LightCycler480 System software and the average of the triplicates was calculated. The relative quantification was determined by the ΔΔCT method.

Source of Microarray Data
Pain genes (PG): The pain gene list was retrieved from a previous study using the same list to predict potential genes related to mediating masseter inflammation-induced pain. This pain gene list contains 685 genes, which mainly includes central and peripheral inflammatory responses and pain mood and affect, human genes related to transmission of pain signals (see Suppl Table 1 for the full list of genes).

Sensory neuronal genes (SN): The sensory neuronal gene list was retrieved from a previous study by magnetic cell sorting (MACS) to separate neuronal cells from non-neuronal cells from mouse DRG. According to this study, MACS successfully segregated neuronal cells from non-neuronal cells from mouse DRGs. This procedure can enrich the neuronal population up to 95% compared with 10% before sorting. Transcriptome analysis further confirmed that a lot of genes were enriched in the neuronal population collected through MACS. We selected genes that showed an increase in expression by >40% according to the criterion described by Chung et al (see Suppl Table 2 for the full list of genes).

TRPV1-lineage neuronal genes (VL): The TRPV1-lineage neuronal genes list was retrieved from a study which identified a group of genes enriched in TRPV1 expressing nociceptive sensory neurons. By using mouse lines selectively labeling or ablating TRPV1 lineage neurons, Goswami et al identified a group of genes enriched in VL sensory neurons. We screened genes that are enriched >3-fold in VL neurons compared to non-VL neurons according to a study by Chung et al (see Suppl Table 3 for the full list of genes).
Protein–Protein Interaction (PPI) Network Analysis

The Search Tool for the Retrieval of Interacting Genes (STRING) is used to provide information regarding predicted and experimental interactions of proteins and the prediction method of this database is from neighborhood, gene fusion, co-occurrence, co-expression experiments, databases, and text mining. By setting the Combination score >0.7 as the reliability threshold value, the web based STRING database (http://string-db.org/) was used to produce PPI predictions after uploading the union gene list to the search bar.35 Based on the interplayed relationships, a PPI network was established and then visualized using the Cytoscape software.36 The connectivity degree of each protein, namely the number of proteins it connected, was calculated to evaluate its importance in this network.

Statistical Analysis

Data in graphs are expressed as means±SEM. One- or two-way ANOVA followed by Tukey’s post-hoc test was used for comparisons among groups ≥3. Student’s t-test was used for comparisons between two groups. The data from different groups were verified for normality using Kolmogorov–Smirnov test. If not normally distributed, a non-parametric test (Mann Whitney U-test) was used. The comparison is considered significantly different if the p-value is less than 0.05.

Results

The Establishment of a Rat Model of CRPS-I and the Evaluation of the Animals’ Nocifensive Behavior

We first established the rat CPIP model to mimic human CRPS-I following methods described before.16,22 An O-ring with 7/32 inch internal diameter was tightly passed around the right hind limb just proximal to the ankle joint and applied for 3 hours. During the ligation, the right hind limb displayed obvious cyanosis (an indication of tissue hypoxia) and edema (Figure 1A). The edema persisted for 3 days and gradually returned back to normal (Figure 1B and C). The PWT (paw withdrawal threshold) of ipsilateral hind paws of CPIP model group rats was significantly reduced on Day 1 compared with the sham group and lasted over 7 days (Figure 1D and F). Moreover, the contralateral hind paw also showed a significant reduction in PWT on Day 1 compared with sham rats and persisted over 7 days (Figure 1E and G), which is a clear sign of MIP. The contralateral mechanical allodynia developed in all CPIP model rats we had observed. These results were consistent with previous studies,15–17 demonstrating the successful establishment of the CPIP model and the presence of MIP in model rats.

Pathological Evaluation of Ipsilateral and Contralateral DRG Neurons Innervating the Hind Paws

We sacrificed the rats on Day 7 and harvested bilateral L4–6 DRG. We first performed immunostainings to examine whether any neuronal damage occurred in the DRG. We used ATF3, a widely used marker for neuronal damage, for the examination. As shown in Figure 2A–C, we did not identify any ATF3 positively stained neurons in ipsilateral or contralateral L4–6 DRG of CPIP model rats compared with sham rats. For positive control, in one of our recent studies, we stained the DRG with ATF3 from paclitaxel-treated rats, a rat model for chemotherapy-induced peripheral neuropathy and well known for its peripheral neuropathy. We found the number of ATF3 positively expressed neurons was significantly increased in DRG of paclitaxel-treated rats vs control rats.27 Therefore, these results indicated no neuronal damage occurred in bilateral DRG neurons of the CPIP model rats.

Examination of Gene Expression Profile Changes in Contralateral DRG from CPIP Model Rats via RNA-Seq

To gain further insights into the mechanisms underlying MIP of CPIP model rats, we harvested contralateral L4-6 DRG at Day 7 from CPIP model and sham rats and analyzed the gene expression profiles via RNA-Seq. We managed to obtain high quality RNA for RNA-Seq analysis (Suppl Figure 1). RNA-Seq generated approximately 23.9 million raw reads from each sample. The ratio of clean reads reached above 98.0% (Table 2). Over 90% of bases had a quality score ≥Q30 and over 94% of the clean reads were mapped to the rat genome. In all, a total of 23, 267 genes were successfully mapped and identified from RNA-Seq (Suppl Table 4). We then filtered out the differentially expressed genes (DEGs) with the criteria of fold change ≥1.5 or ≤0.667 and q-value≤0.001 (Suppl Table 5). We displayed the DEGs of the CPIP group vs sham group in the volcano plot as shown in Figure 3A. In all, 527 DEGs (including
245 up- and 282 down-regulated) were identified from the CPIP group vs sham group (Figure 3A). We further summarized and plotted the identified DEGs in a heat map as shown in Figure 3B. Cluster analysis indicated a high level of consistency within CPIP or sham group samples, but a clear separation between these two groups (Figure 3B). These results indicated that we have obtained a high quality RNA-Seq dataset that can be further used for bioinformatics analysis.

Analysis of DEGs from Contralateral DRG of CPIP Model Rats

Among the DEGs we identified, a certain number of genes were reported to participate in pain mechanisms, which include: Cxcl14 (C-X-C motif chemokine 14 precursor, fold change=3.2), Cxcl13 (C-X-C motif chemokine 13 precursor, fold change=2.6), Tlr5 (Toll-like receptor 5, fold change=2.6), Ngf (Nerve growth factor, fold change=2.3), and Tlr8 (Toll-like receptor 8, fold change=2.0).
We further analyzed the RNA-Seq dataset and identified 167 genes (63 up-regulated and 104 down-regulated gene) showing expression changes >10-fold, including Tsr2 (TSR2 Ribosome Maturation Factor, fold change=109,177.8), Aph1b (Gamma-Secretase Subunit APH-1B, fold change=436.9), etc. In total, 124 genes had expression changes between 5- and 10-fold, including 40 up-regulated and 84 down-regulated genes. The top 20 up- or 20 down-regulated DEGs are summarized in Tables 3 and 4. These data suggest that the DEGs are probably correlated with MIP pathogenesis.

RNA-Seq Data Validation by Means of qPCR

We then set to validate the RNA-Seq dataset by means of qPCR. We randomly selected eight up-regulated genes (Tbx18, Slfn1, Gli2, Stk32b, Asgr2, Smoc2, Osr2, and Sned1) and four down-regulated genes (Myl1, Myom2, Capg, and Retsat) from the DEGs list and verified their expression by qPCR. The results of qPCR showed that the expression of Tbx18, Slfn1, Gli2, Stk32b, Asgr2, Smoc2, Osr2, and Sned1 were all significantly up-regulated, whereas Myl1, Myom2, Capg, and Retsat were all significantly down-regulated in contralateral DRG of CPIP model rats vs sham rats (Figure 4A and B), which is consistent with the RNA-Seq dataset. We then proceeded to evaluate some representative genes which were known to contribute to pain or neuroinflammation. These genes include Gpr183, Thr8, Egfr, Cxcl13, Fcgr1a, and Siglec1. qPCR testing showed that the expression of these genes were all significantly increased in CPIP model rats vs sham rats, which is consistent with the RNA-Seq result (Figure 4C). Therefore, these results indicated that the RNA-Seq dataset we obtained was reliable.

Figure 2 The CPIP model rats did not show any neuronal damage in bilateral DRG neurons innervating the hind limbs. (A) Representative immunostaining pictures showing ATF3 antibody (green) staining of ipsilateral and contralateral DRG from the sham group and CPIP model group. NeuN was used to label neurons (red). (B) Summary of the number of ATF3 positive neurons per observation field in ipsilateral DRG. (C) Summary of the number of ATF3 positive neurons per observation field in contralateral DRG. Scale bar indicates 100 μm. n=6 rats/group.

Abbreviations: CPIP, chronic post-ischemic pain; DRG, dorsal root ganglia.
Function and Pathway Analysis of DEGs from Contralateral DRGs of CPIP Model Rats

In order to gain more insights into the molecular mechanisms underlying MIP of CRPS-I, gene ontology (GO) enrichment analysis was performed to analyze the DEGs from contralateral DRGs of CPIP model rats vs sham rats. GO enrichment analysis indicated that the mostly enriched biological process among up-regulated DEGs included immune system process, innate immune response, and cell adhesion, etc. (Figure 5A). The mostly enriched molecular function among up-regulated DEGs included low-density lipoprotein particle binding, carbohydrate binding, and heparin binding, etc. (Figure 5B). The mostly enriched cellular function among up-regulated DEGs included the extracellular region and extracellular matrix, etc. (Figure 5C). On the other hand, the mostly enriched biological process among down-regulated DEGs included muscle contraction, sarcomere organization, and ossification, etc. (Figure 5D). The mostly enriched molecular function of down-regulated DEGs included actin binding, a structural constituent of muscle and actin filament binding, etc. (Figure 5E). The mostly enriched cellular function of down-regulated DEGs included Z disc, myofibril, and M band, etc. (Figure 5F). The DEGs allocated to each category of GO analysis are summarized in Suppl Table 6. These results indicated that immune response occurred in contralateral DRG and may possibly be related with MIP pathogenesis.

We then performed KEGG analysis to analyze the DEGs from contralateral DRG of the CPIP model rats. KEGG analysis indicated that the up-regulated DEGs were involved in complement and coagulation cascades, phagosome and osteoclast differentiation, etc. (Figure 6A). In contrast, the down-regulated DEGs were involved in cardiac muscle contraction, apelin signaling pathway and glucagon signaling pathway, etc. (Figure 6B, Suppl Table 7). We further performed gene set enrichment analysis (GSEA) of the up-regulated DEGs. Suppl Figure 2 lists the most significantly enriched pathways of these DEGs (NES>1.0, FDR≤0.25), including complement and coagulation cascades and Toll-like receptor signaling pathway, etc.

Next, we aim to focus our analysis more on the genes related with pain processing. We were able to retrieve three datasets that summarized genes enriched in small-diameter primary sensory DRG neurons (SN), TRPV1-lineage

| Sample  | Total Raw Reads (M) | Total Clean Reads (M) | Clean Reads Q30 (%) | Clean Reads Ratio (%) | Total Mapping (%) |
|---------|---------------------|-----------------------|---------------------|-----------------------|------------------|
| CPIP1   | 23.92               | 23.74                 | 93.65               | 99.22                 | 94.65            |
| CPIP2   | 23.92               | 23.74                 | 93.86               | 99.21                 | 94.83            |
| CPIP3   | 23.92               | 23.73                 | 93.15               | 99.24                 | 94.81            |
| CPIP4   | 23.92               | 23.74                 | 93.21               | 98.88                 | 94.08            |
| Sham1   | 23.92               | 23.66                 | 94.01               | 99.19                 | 94.75            |
| Sham2   | 23.92               | 23.73                 | 93.59               | 99.2                  | 94.66            |
| Sham3   | 23.92               | 23.75                 | 93.58               | 99.27                 | 94.71            |
| Sham4   | 23.92               | 23.74                 | 93.15               | 99.24                 | 94.81            |

Figure 3 Gene expression profiling by RNA-Seq in contralateral DRG of CPIP model rats. (A) Volcano plot illustrating gene expression profiles in contralateral DRG of CPIP model group vs sham group. Red and blue dots show up- and down-regulated DEGs, respectively. Gray dots indicate non-DEGs. (B) Heat map showing the hierarchical clustering of DEGs from CPIP and sham groups and within groups.

Abbreviations: RNA-Seq, RNA-sequencing; DRG, dorsal root ganglia; CPIP, chronic post-ischemic pain; DEGs, differentially expressed genes.
| Upregulated Gene | Gene ID  | Location                        | log₂ Fold-Change (CPIP/Sham) | Q Value  | Official Gene Name (NCBI)                                                                 |
|------------------|---------|---------------------------------|-----------------------------|----------|------------------------------------------------------------------------------------------------|
| Tsr2             | 317418  | 4:20141406–20146082             | 16.73631777                 | 3.05E-48 | TSR2, 20S rRNA accumulation, homolog (S. cerevisiae)                                         |
| LOC100912618     | 100912618 | 4:5867350–5869085               | 10.69826964                 | 1.77E-12 | ubiquitin-conjugating enzyme E2 variant 1-like                                               |
| LOC100910581     | 100910581 | 4:21987993–21989200             | 9.114037693                 | 6.00E-51 | Protein phosphatase 1 regulatory subunit 35-like                                             |
| Aph1b            | 300802  | 4:72508008–7259921              | 8.77101005                  | 5.97E-42 | aph-1 homolog B, gamma secretase subunit                                                    |
| LOC103691556     | 103691556 | 4:144191722–144211986           | 7.608251098                 | 8.58E-60 | Mothers against decapentaplegic homolog 9                                                  |
| LOC102550456     | 102550456 | 4:21748602–22021862             | 7.14204003                  | 4.65E-16 | TSC22 domain family protein 4-like                                                          |
| LOC10349606      | 10349606 | 4:216628204–166282845           | 6.69115347                  | 3.43E-12 | 60S ribosomal protein L7a-like                                                              |
| LOC100911233     | 100911233 | 4:33876697–33909836             | 6.41761766                  | 2.65E-10 | Cell division cycle and apoptosis regulator protein 1-like                                  |
| LOC100912399     | 100912399 | 4:43938500–4400199              | 6.383284264                 | 4.34E-10 | Mitogen-activated protein kinase kinase kinase 1-like                                        |
| Potef            | 684969  | 4:24780521–24783147             | 6.285873408                 | 1.68E-09 | POTE ankyrin domain family, member F                                                         |
| Hmgn5            | 100910616| 4:80134557–80142902             | 5.97262604                  | 7.99E-08 | High mobility group nucleosome binding domain 5                                              |
| LOC100384106     | 100384106 | 4:90957132–90962541             | 5.585249332                 | 3.78E-06 | Alpha-ketoglutarate-dependent dioxygenase alkB homolog 6                                   |
| LOC10099795      | 10099795 | 4:78550661–78577178             | 5.50305695                  | 7.81E-06 | Colorectal mutant cancer protein-like                                                        |
| LOC100911564     | 100911564 | 4:16314107–16317575             | 5.39657958                  | 1.82E-05 | Glycine N-methyltransferase-like                                                            |
| LOC100361265     | 100361265 | 4:71676810–7168016              | 5.30501238                  | 1.26E-09 | rCG64281-like                                                                               |
| RGD1584023       | 690146  | 4:94827988–94840706             | 5.00359585                  | 2.68E-04 | Similar to zinc finger protein 11B                                                           |
| RGD1560795       | 297402  | 4:116933277–116936466           | 4.968015878                 | 3.36E-04 | similar to Sepiapterin reductase (SPR)                                                       |
| LOC102552708     | 102552708 | 4:134996–135398                 | 4.877490295                 | 5.64E-04 | DNA-directed RNA polymerase II subunit GRINLIA-like                                           |
| Zp2              | 81828   | 4:18999906–18991165             | 4.46124948                  | 2.03E-05 | zona pellucida glycoprotein 2                                                               |
| Slc25a36ll       | 364991  | 4:37019755–37022003             | 3.968951847                 | 6.98E-10 | Solute carrier family 25 (pyrimidine nucleotide carrier), member 36-like                     |
Table 4 The Detailed Information of the Top 20 Down-Regulated DEGs

| Downregulated Gene | Gene ID   | Location                  | log<sub>2</sub> Fold-Change (CPIP/Sham) | Q Value     | Official Gene Name (NCBI)                                                                 |
|---------------------|-----------|---------------------------|---------------------------------------|-------------|------------------------------------------------------------------------------------------|
| LOC100909761        | 100909761 | 4:78661643–78681196       | -8.814802024                          | 5.59E-86    | Myotilin-like                                                                            |
| Myot                | 291605    | 4:35573978–35593541       | -8.321037008                          | 2.02E-32    | Myotilol                                                                                |
| LOC100910177        | 100910177 | 4:52919250–52919654       | -8.04339285                           | 1.43E-27    | Dolichol-phosphate mannosyl transferase subunit 3-like                                   |
| Mb                  | 59108     | 4:11810163–118108864      | -7.245234184                          | 0           | Myoglobin                                                                                |
| Myh2                | 691644    | 4:53711895–53738164       | -7.02013868                           | 0           | Myosin heavy chain 2                                                                     |
| LOC108348161        | 108348161 | 4:5276735–52778693        | -6.98689986                           | 1.22E-14    | Pyranoyl-CoA hydroxylase-interacting protein                                              |
| LOC103694902        | 103694902 | 2:1481–2979              | -6.605321706                         | 1.95E-196   | Ubiquitin-conjugating enzyme E2 B                                                         |
| LOC103690173        | 103690173 | 2:1373–18580             | -6.475307726                          | 1.07E-10    | Zinc finger protein 280B-like                                                            |
| LOC100359951        | 100359951 | 2:10120441–1012567        | -6.3644056                            | 8.02E-10    | Ribosomal protein S20-like                                                               |
| LOC100909700        | 100909700 | 4:81609177–81627763       | -6.201682182                          | 4.93E-09    | CDI 77 antigen-like                                                                     |
| Tnxb                | 308622    | 4:12915781–12961680       | -6.187161229                          | 3.36E-34    | Taxilin beta                                                                            |
| Gsco1               | 29658     | 4:95921479–95934170       | -6.167231672                          | 4.38E-17    | Calcium voltage-gated channel auxiliary subunit gamma 1                                  |
| Myl1                | 56781     | 4:73937820–73958480       | -6.018352279                          | 0           | Myosin, light chain 1                                                                   |
| Nmrk2               | 100912521 | 4:11382966–11386170       | -5.977306671                          | 5.91E-08    | Nicotinamide riboside kinase 2                                                           |
| LOC100361543        | 100361543 | 4:3726374–37262470        | -5.95800371                           | 9.12E-08    | RhO activator C1 lor59-like                                                              |
| Myl2                | 363925    | 4:39947717–39966734       | -5.951502981                          | 9.79E-08    | Myosin light chain 2                                                                    |
| Igfn1               | 304823    | 4:52791184–52823037       | -5.912190057                          | 7.21E-85    | Immunoglobulin-like and fibronectin type III domain containing 1                         |
| Tnnc2               | 2063982   | 4:16124360–16124564       | -5.911770486                          | 0           | Troponin C2, fast skeletal type                                                          |
| Ucp3                | 25708     | 4:16548292–165495895      | -5.87994972                           | 3.84E-14    | Uncoupling protein 3                                                                    |
| LOC100911166        | 100911166 | 4:112519789–112524281     | -5.70387223                           | 1.25E-06    | RNA pseuduridylate synthase domain-containing protein 2-like                            |
nociceptors (VL), and pain-related genes (PG), respectively. We then compared the DEGs we identified from RNA-Seq with these three datasets. We identify that 19 DEGs were related with PG and Stoml3, Fosb, and Gdnf are among the genes most up-regulated (Figure 7A, Suppl Table 8). We identified four DEGs were related with SN and Eno3 showed the most down-regulation (Figure 7A, Suppl Table 8). We identified seven genes were related with VL and Fosb showed the most up-regulation (Figure 7A, Suppl Table 8). PPI analysis was conducted on these 26 genes and the major hub genes identified from the network included Mmp9, Egr1, Ngf, etc. (Figure 7B). These data suggest that these specific DEGs related with pain, small-diameter primary sensory DRG neurons, and TRPV1-lineage nociceptors may probably contribute to MIP mechanisms.

Discussion

In this study, we established the rat CPIP model to replicate CRPS-I. We found the model rats developed obvious MIP in contralateral hind paws. We then performed expression profiling of the DRG innervating the contralateral hind limb of the model rats by RNA-Seq. We identified the DEGs and validated the expression by means of qPCR. We then studied the major functions or signaling pathways that these DEGs were involved in. Lastly, by comparing with published datasets that summarized genes enriched in pain mechanisms, we further sorted out the genes which might contribute to nociception and pain processing. Thus, we provided by far the first study to profile gene expression changes and performed pathway analysis of contralateral DRG for investigating MIP mechanisms.

CRPS-I is a chronic and devastating pain condition that usually affects the extremities of the patients. One feature of CRPS-I patients is the symptom of MIP. CRPS-I patients may develop increased sensitivity to chemical, thermal, and mechanical stimuli in bilateral extremities. In order to facilitate mechanistic studies of CRPS-I, a rat chronic post-ischemic pain (CPIP) model was developed by applying prolonged hind paw ischemia and reperfusion to mimic CRPS-I. The rat CPIP models exhibit several
key features that resemble CRPS-I, including early hind paw edema, vascular disturbance and blood flow dysfunction in the hind paw, persistent bilateral mechanical allodynia and heat hyperalgesia, increased sensitivity to capsaicin treatment, etc. At present, the CPIP model has become a commonly used animal model for mechanistic studies of CRPS-I. We and others found that the CPIP model rats develop robust MIP symptoms in the unaffected hind paw, including mechanical and thermal hypersensitivities. Therefore, in the present study, we established the rat CPIP model and made good use of it for a mechanistic study of MIP.

We first performed a pathological analysis to examine whether there was any neuronal damage which occurred in DRG innervating bilateral hind paws of CPIP model rats. Immunostaining showed that the expression of ATF3, a well-established neuronal damage marker, is not altered in ipsilateral or contralateral DRG of CPIP model rats, suggesting bilateral DRG neurons remain intact in CPIP model rats. In an earlier study,Coderre et al found no
These findings are consistent with the clinical definition that CRPS-I patients have no known or identifiable peripheral nerve injury. Thus, this result excludes the possibility that neuronal damage may contribute to MIP in CPIP model rats.

Peripheral mechanisms have been proposed to contribute to MIP. For example, in a spinal nerve ligation (SNL) animal model for neuropathic pain, TNF-α can be produced from ipsilateral injured DRG and diffuses to the contralateral side via cerebrospinal fluid. TNF-α then activates satellite cells to produce NGF, which in turn promotes nociceptor excitability on the contralateral side and induces MIP. Although these findings suggest that peripheral satellite glial cells and pro-inflammatory cytokines are important for MIP, it still remains unclear how contralateral DRG is affected during MIP. Therefore, we performed a genome-wide expression profiling of the DRG that innervate the contralateral hind limbs of the rat CPIP model by means of RNA-Seq.

According to GO enrichment analyses of DEGs in contralateral DRG, we found that the mostly enriched biological processes of up-regulated genes were mainly involved in the immune system process, innate immune response, cell adhesion, response to lipopolysaccharide, inflammatory response, etc. This information indicates that immune and inflammatory responses, which can cause neuroinflammation and pain, take place in contralateral DRG. This finding is similar with our recent study which identified lipopolysaccharide and inflammatory response as the predominant biological processes in ipsilateral DRG of CPIP model rats. It is known that neuroinflammation, including inflammatory cytokine/chemokine release, glial cell activation, and inflammatory cell infiltration in the sensory nerve system, make important contributions to the initiation and maintaining phase of chronic pain. Therefore, this result suggests that neuroinflammation in contralateral DRG may constitute an important mechanism for MIP of CPIP model rats.

In addition, KEGG pathway analysis indicated that one of the mostly enriched pathways that these DEGs participate in is “phagosome”. This finding is similar with our recent studies showing that phagosome is a major signaling pathway which occurred in ipsilateral DRG and spinal cord dorsal horn (SCDH) of CPIP model rats. Similar findings were also reported in SCDH of an animal model of neuropathic pain. Itgam is a well-established marker gene for monocytes and macrophages and is involved in the phagosome process. In this study, we found that Itgam gene expression is significantly up-regulated in contralateral DRG of CPIP model rats. This implies that macrophage or monocyte infiltration may likely take place in contralateral DRG of CPIP model rats. Macrophages or monocytes can infiltrate into peripheral tissues and sensory ganglia, where they release an array of inflammatory cytokines and reactive oxygen species (ROS) products. These products activate or sensitize peripheral sensory neurons to produce or enhance pain through neuro-immune crosstalk. Therefore, we speculate that macrophage or monocyte infiltration may occur in contralateral DRG, which could contribute to MIP in CPIP model rats. Further studies using specific markers for macrophages or monocytes will be needed to confirm their infiltrations into contralateral DRG.

In our study, the RNA-Seq identified that Ngf gene is significantly up-regulated in contralateral DRG of CPIP

---

**Figure 6** KEGG pathway analysis of identified DEGs from contralateral DRG. (A) Bubble plots showing the top 10 pathways of up-regulated DEGs identified by KEGG. (B) Bubble plots showing the top 10 pathways of down-regulated DEGs identified by KEGG. Larger bubbles indicate higher number of genes and vice versa. The color of each bubble reflects significance as indicated (q-value).

**Abbreviations:** KEGG, Kyoto Encyclopedia of Genes and Genomes; DEGs, differentially expressed genes; DRG, dorsal root ganglia.
NGF is a neurotrophic factor and neuropeptide implicated in a wide range of development and maintenance functions. NGF can be released upon tissue inflammation and is implicated in chronic pain. NGF sensitizes nociceptors and promotes their excitability by up-regulating TRPV1 and Nav1.8 channel expression and activity via acting on the TrkA receptor.

In a previous study, Cheng et al found that TNF-α produced from ipsilateral injured DRG of a rat spinal nerve ligation model can diffuse to the contralateral side via cerebrospinal fluid and activates satellite cells to produce NGF, which promotes nociceptor excitability on the contralateral side and induces MIP. Their study suggested that NGF expression is up-regulated in contralateral DRG and contributes to the MIP mechanism. In the present study, we found that the Ngf gene was significantly up-regulated in the contralateral DRG of CPIP model rats, a result consistent with Cheng et al’s findings. Thus, our result suggests that NGF may be potentially involved in mediating MIP of CPIP model rats.

We continued to explore other potential genes involved in MIP. By means of RNA-Seq and qPCR validation, we found that chemokine Cxcl13 gene expression showed significant up-regulation in contralateral DRG. CXCL13 is known as a B-cell-attracting chemokine that acts upon its receptor CXCR5 to exert biological functions. Recent
studies identified that the CXCL13/CXCR5 axis is present in peripheral sensory ganglia and spinal cord and contributes to chronic pain. Genetic knockout or knockdown of CXCL13/CXCR5 significantly reduced chronic pain as well as glial cell over-activation in SCDH in animal models of neuropathic pain. Intrathecal CXCL13 injection can provoke thermal and mechanical hypersensitivities in naïve animals. Moreover, it is found that CXCL13 is increased in DRG neurons of CFA-induced inflammatory model mice and acts upon CXCR5 in DRG neurons to activate the p38-MAP kinase, which enhances Nav1.8 channel expression and contributes to chronic pain. Therefore, our findings suggest CXCL13 released from contralateral DRG may be another possible contributor to MIP of CPIP model rats.

Single-cell RNA-sequencing is a powerful technique that has greatly facilitated the identification of molecular profiles of heterogeneous cells, especially on the transcription level of single cells. Recently, two groups published single-cell RNA-sequencing results of DRG neurons. These studies provide novel insights into understanding the biological function of somatosensory neurons, particularly for the nociceptors, and suggest that neuron types are defined by their transcriptomic, morphological, and functional characteristics. We hope that single-cell RNA-sequencing may be applied in the MIP study in the future, which could provide detailed transcriptome profiles of single nociceptors in conditions of MIP.

In conclusion, to our knowledge, this is the first study that performs expression profiling of gene expression changes in contralateral DRG of an animal model of CRPS-I by RNA-Seq to explore MIP mechanisms. This study identifies a number of genes and signaling pathways in contralateral DRG that may possibly contribute to MIP. Thus, this study may provide novel insights into understanding the mysterious mechanisms underlying MIP.

Abbreviations
CRPS-I, Complex regional pain syndrome type-I; MIP, Mirror-image pain; CPIP, Chronic post-ischemic pain; RNA-Seq, RNA-sequencing; qPCR, Real-time quantitative PCR; DRG, Dorsal root ganglia; DEGs, Differentially expressed genes; PWT, Paw withdrawal threshold; QC, Quality control; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; GSEA, Gene set enrichment analysis; PG, Pain genes; SN, Sensory neuronal genes; VL, TRPV1-lineage neuronal genes; PPI, Protein–protein interaction; STRING, Search Tool for the Retrieval of Interacting Genes; BP, Biological processes; MF, Molecular function; CC, Cellular component; ROS, reactive oxygen species.

Data Sharing Statement
The key data are contained in the figures, tables, and additional files. The datasets used and/or analyzed during this study can be further obtained from the corresponding author on reasonable request.

Ethics Approval and Consent to Participate
All experimental procedures were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. 8023, revised 1978) and approved by the Animal Ethics Committee of Zhejiang Chinese Medical University (Permission Number: ZSLL-2017-183).

Acknowledgment
We thank the Academy of Chinese Medicine Sciences, Zhejiang Chinese Medical University for the technical support to our work.

Author Contributions
All authors made substantial contributions to the conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; gave final approval of the version to be published; and agree to be accountable for all aspects of the work.

Funding
This project was supported by the National Natural Science Foundation of China (81873365&81603676), Zhejiang Provincial Natural Science Funds for Distinguished Young Scholars (LR17H270001), Zhejiang Provincial Natural Science Funds (LQ21H270004), Research Projects from Zhejiang Chinese Medical University (Q2019J01, 2021JKZDZC07, KC201943), Natural Science Foundation of Hebei Province (H20206360), Projects from Health and Family Planning Commission of Hebei Province (20201069) and GuangDong Natural Science Foundation (2018A030313092).
Disclosure
The authors declare no conflicts of interest for this work.

References
1. Huang D, Yu B. The mirror-image pain: an unclered phenomenon and its possible mechanism. Neurosci Biobehav Rev. 2010;34:528–532. doi:10.1016/j.neubiorev.2009.10.011
2. Milligan ED, Twining C, Chacur M, et al. Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. J Neurosci. 2003;23:1026–1040. doi:10.1523/JNEUROSCI.23-03-01026.2003
3. Kambiz S, Brakkee EM, Duraku LS, Hovius SE, Ruigrok TJ, Waldbeem ET. Mirror-image pain after nerve reconstruction in rats is related to enhanced density of epidermal peptidergic nerve fibers. Exp Neurol. 2015;267:87–94. doi:10.1016/j.expneurol.2015.02.033
4. Cheng CF, Cheng JK, Chen CY, et al. Mirror-image pain is mediated by nerve growth factor produced from tumor necrosis factor alpha-activated satellite glia after peripheral nerve injury. Pain. 2014;155:906–920. doi:10.1016/j.pain.2014.01.010
5. Rotpenpian N, Tapechum S, Vattarakorn A, et al. Evolution of CRPS syndrome type 1. J Neurosci Biobehav Rev. 2003;26.2001026.2003
6. Hampf G, Bowsher D, Wells C, Miles J. Sensory and autonomic measurements in idiopathic trigeminal neuralgia before and after radiofrequency thermocoagulation: differentiation from some other causes of facial pain. Pain. 1990;40:241–248. doi:10.1016/0304-3959(90)90121-X
7. Maleki J, LeBel AA, Bennett GJ, Schwartzman RJ. Patterns of spread in complex regional pain syndrome, type I (reflex sympathetic dystrophy). Pain. 2000;88:259–266. doi:10.1016/S0304-3959(00)00332-8
8. Ott S, Madhofner C. Signs and symptoms in 1043 patients with complex regional pain syndrome. J Pain. 2018;19:599–611. doi:10.1016/j.jpain.2018.01.004
9. Birklein F, Ajit SK, Goebel A, Perez R, Sommer C. Complex regional pain syndrome - phenotypic characteristics and potential biomarkers. Nat Rev Neurol. 2018;14:272–284. doi:10.1038/nrneurol.2018.20
10. Coderre TJ, Bennett GJ. A hypothesis for the cause of complex regional pain syndrome-type I (reflex sympathetic dystrophy): pain due to deep-tissue microvascular pathology. Pain Med. 2010;11:1224–1238. doi:10.1111/j.1536-4637.2010.00911.x
11. Urits I, Shen AH, Jones MR, Viswanath O, Kaye AD. Complex regional pain syndrome, current concepts and treatment options. Curr Pain Headache Rep. 2018;22:10. doi:10.1007/s11916-018-0667-7
12. Terkelsen AJ, Gierzdhulten J, Finnerup NB, Hojlund AP, Jensen TS. Bilateral hypersensitivity to capsaicin, thermal, and mechanical stimuli in unilateral complex regional pain syndrome. Anesthesiology. 2014;120:1225–1236. doi:10.1097/ALN.0000000000000220
13. Veldman PH, Reynen HM, Arntz IE, Goris RJ. Signs and symptoms of reflex sympathetic dystrophy: prospective study of 829 patients. Lancet. 1993;342:1012–1016. doi:10.1016/0140-6736(93)92877-V
14. Yin C, Hu Q, Liu B, et al. Transcriptome profiling of dorsal root ganglia in a rat model of complex regional pain syndrome type-I reveals potential mechanisms involved in pain. J Pain Res. 2019;12:1201–1216. doi:10.2147/JPR.S188758
15. Hu Q, Wang Q, Wang C, et al. TRPV1 channel contributes to the behavioral hypersensitivity in a rat model of complex regional pain syndrome type I. Front Pharmacol. 2019;10:453.
16. Coderre TJ, Xanthos DN, Francis L, Bennett GJ. Chronic post-ischemia pain (CPIP): a novel animal model of complex regional pain syndrome-type I (CRPS-I; reflex sympathetic dystrophy) produced by prolonged hindpaw ischemia and reperfusion in the rat. Pain. 2004;112:94–105. doi:10.1016/j.pain.2004.08.001
17. Chen R, Yin C, Hu Q, et al. Expression profiling of spinal cord dorsal horn in a rat model of complex regional pain syndrome-type I uncovers potential mechanisms mediating pain and neuroinflammation responses. J Neuroinflammation. 2020;17:162. doi:10.1186/s12974-020-01834-0
18. Wang J, Zheng X, Liu B, et al. Electroacupuncture alleviates mechanical allodynia of a rat model of CRPS-I and modulates gene expression profiles in dorsal root ganglia. Front Neurol. 2020;11:580997. doi:10.3389/fneur.2020.580997
19. Janacek R. Signaling mechanisms in mirror image pain pathogenesis. Annu Neurosci. 2011;18:123–127. doi:10.5214/ans.0972.7531,11183010
20. Choi HS, Roh DH, Yoon SY, et al. Microglial interleukin-1beta in the ipsilateral dorsal horn induces the development of mirror-image contralateral mechanical allodynia through astrocyte activation in a rat model of inflammatory pain. Pain. 2015;156:1046–1059. doi:10.1097/j.pain.0000000000001418
21. Su YS, Mei HR, Wang CH, Sun WH. Peripheral 5-HT3 mediates mirror-image pain by a cross-talk with acid-sensing ion channel 3. Neuropharmacology. 2018;130:92–104. doi:10.1016/j.neuropharm.2017.11.044
22. Hu Q, Zheng X, Chen R, et al. Chronic post-ischemia pain model for complex regional pain syndrome-type I in rats. J Vis Exp. 2020;2015;e60562. doi:10.3791/60562
23. Chai W, Tai Y, Shao X, et al. Electroacupuncture alleviates pain responses and inflammation in a rat model of acute gout arthritis. Evid Based Complement Alternat Med. 2018;2018:2598975. doi:10.1155/2018/2598975
24. Chapman SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods. 1994;53:55–63. doi:10.1016/0165-2700(94)90144-9
25. Dixon WJ. Efficient analysis of experimental observations. Ann Rev Pharmacol Toxicol. 1980;20:441–462. doi:10.1146/annurev.ar.20.040180.002301
26. Hu Q, Zheng X, Li X, et al. Electroacupuncture alleviates mechanical allodynia in a rat model of complex regional pain syndrome type-I via suppressing spinal CXCL12/CXCR4 signaling. J Pain. 2020;21:1060–1074. doi:10.1016/j.jpain.2020.01.007
27. Li Y, Yin C, Liu B, et al. Transcriptome profiling of long noncoding RNAs and miRNAs in spinal cord of a rat model of peltaxtol-induced peripheral neuropathy identifies potential mechanisms mediating neuroinflammation and pain. J Neuroinflammation. 2021;18:48. doi:10.1186/s12974-021-02098-y
28. Chen W, Ding H, Zhou X, Lin H, Chou KC. iRNA(m6A)-PseDNC: identifying N(6)-methyladenosine sites using pseudo dinucleotide composition. Anal Biochem. 2018;561–562:59–65. doi:10.1016/j.ab.2018.09.002
29. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15455–15450. doi:10.1073/pnas.0506580102
30. Yin C, Liu B, Wang P, et al. Eucalyptol alleviates inflammation and pain responses in a mouse model of gout arthritis. Br J Pharmacol. 2020;177:2042–2057. doi:10.1111/bph.14967
31. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–408. doi:10.1006/meth.2001.1262
32. Chung MK, Park J, Asgar J, Ro JY. Transcriptome analysis of trigeminal ganglia following masseter muscle inflammation in rats. Mol Pain. 2016;12:1744806916686526.
33. Thakur M, Crow M, Richards N, et al. Defining the nociceptor transcriptome. Front Mol Neurosci. 2014;7:87. doi:10.3389/fnmol.2014.00087
34. Goswami SC, Mishra SK, Marie D, et al. Molecular signatures of mouse TRPV1-lineage neurons revealed by RNA-Seq transcriptome analysis. J Pain. 2014;15:1338–1359.
35. Franceschini A, Szklarczyk D, Frankild S, et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. *Nucleic Acids Res*. 2013;41:D808–15. doi:10.1093/nar/gks1094

36. Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. * Genome Res.* 2003;13:2498–2504. doi:10.1101/gr.1239303

37. Xu X, Tao X, Huang P, et al. N-methyl-d-aspartate receptor subunit 2B on keratinocyte mediates peripheral and central sensitization in chronic post-ischemic pain in male rats. *Brain Behav Immun*. 2020;87:579–590. doi:10.1016/j.bbi.2020.02.003

38. Donnelly CR, Andressen AS, Chen G, et al. Central nervous system targets: glial cell mechanisms in chronic pain. *Neurotherapeutics*. 2020;17:846–860.

39. Matsuda M, Huh Y, Ji RR. Roles of inflammation, neurogenic inflammation, and neuroinflammation in pain. *J Anesth*. 2019;33:131–139.

40. Chen R, Yin C, Fang J, Liu B. The NLRP3 inflammasome: an emerging therapeutic target for chronic pain. *J Neuroinflammation*. 2021;18:84. doi:10.1186/s12974-021-02131-0

41. Ji RR, Chamessian A, Zhang YQ. Pain regulation by non-neuronal cells and inflammation. *Science*. 2016;354:572–577. doi:10.1126/science.aaf8924

42. Du H, Shi J, Wang M, An S, Guo X, Wang Z. Analyses of gene expression profiles in the rat dorsal horn of the spinal cord using RNA sequencing in chronic constriction injury rats. *J Neuroinflammation*. 2018;15:280. doi:10.1186/s12974-018-01316-0

43. Yin C, Liu B, Li Y, et al. IL-33/ST2 induces neutrophil-dependent reactive oxygen species production and mediates gout pain. *Theranostics*. 2020;10:12189–12203. doi:10.7150/thno.48028

44. Trevisan G, Benemsi S, Materazzi S, et al. TRPA1 mediates trigeminal neuropathic pain in mice downstream of monocytes/macrophages and oxidative stress. *Brain*. 2016;139:1361–1377. doi:10.1093/brain/aww038

45. Zhang L, Xie W, Zhang J, et al. Key role of CCR2-expressing macrophages in a mouse model of low back pain and radioulopathy. *Brain Behav Immun*. 2021;91:556–567. doi:10.1016/j.bbi.2020.11.015

46. Yu X, Liu H, Hamel KA, et al. Dorsal root ganglion macrophages contribute to both the initiation and persistence of neuropathic pain. *Nat Commun*. 2020;11:264. doi:10.1038/s41467-019-13839-2

47. Denk F, Bennett DL, McMahon SB. Nerve growth factor and pain mechanisms. *Annu Rev Neurosci*. 2017;40:307–325. doi:10.1146/annurev-neuro-072116-031121

48. Dib-Hajj SD, Black JA, Cummins TR, Kenney AM, Kocsis JD, Waxman SG. Rescue of alpha-SNS sodium channel expression in small dorsal root ganglion neurons after axotomy by nerve growth factor in vivo. *J Neurophysiol*. 1998;79:2668–2676. doi:10.1152/jn.1998.79.5.2668

49. Zhang X, Huang J, McNaughton PA. NGF rapidly increases membrane expression of TRPV1 heat-gated ion channels. *EMBO J*. 2005;24:4211–4223.

50. Jiang BC, Liu T, Gao YJ. Chemokines in chronic pain: cellular and molecular mechanisms and therapeutic potential. *Pharmacol Ther*. 2020;212:107581.

51. Wu XB, Cao DL, Zhang X, et al. CXCL13/CXCR5 enhances sodium channel Nav1.8 current density via p38 MAP kinase in primary sensory neurons following inflammatory pain. *Sci Rep*. 2016;6:34836. doi:10.1038/srep34836

52. Jiang BC, Cao DL, Zhang X, et al. CXCL13 drives spinal astrocyte activation and neuropathic pain via CXCR5. *J Clin Invest*. 2016;126:745–761.

53. Li CL, Li KC, Wu D, et al. Somatosensory neuron types identified by high-coverage single-cell RNA-sequencing and functional heterogeneity. *Cell Res*. 2016;26:83–102. doi:10.1038/cr.2015.149

54. Zheng Y, Liu P, Bai L, Trimmer JS, Bean BP, Ginty DD. Deep sequencing of somatosensory neurons reveals molecular determinants of intrinsic physiological properties. *Neuron*. 2019;103:598–616 e7. doi:10.1016/j.neuron.2019.05.039